These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 1772463

  • 1. Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment.
    Leonhardt W, Hanefeld M, Fischer S, Schulze J, Spengler M.
    Arzneimittelforschung; 1991 Jul; 41(7):735-8. PubMed ID: 1772463
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
    Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fücker K.
    Diabetes Care; 1991 Aug; 14(8):732-7. PubMed ID: 1954810
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
    Hoffmann J, Spengler M.
    Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
    [Abstract] [Full Text] [Related]

  • 4. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
    Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB.
    Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.
    Hoffmann J, Spengler M.
    Diabetes Care; 1994 Jun; 17(6):561-6. PubMed ID: 8082525
    [Abstract] [Full Text] [Related]

  • 7. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
    Coniff RF, Shapiro JA, Seaton TB, Bray GA.
    Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia.
    Leonhardt W, Hanefeld M, Fischer S, Schulze J.
    Eur J Clin Invest; 1994 Aug; 24 Suppl 3():45-9. PubMed ID: 8001628
    [Abstract] [Full Text] [Related]

  • 10. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.
    Costa B, Piñol C.
    Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244
    [Abstract] [Full Text] [Related]

  • 11. Effect of long term acarbose (Bay g 5421) therapy on metabolic control of non insulin dependent (type II) diabetes mellitus.
    Rodier M, Richard JL, Monnier L, Mirouze J.
    Diabete Metab; 1988 Oct; 14(1):12-4. PubMed ID: 3292303
    [Abstract] [Full Text] [Related]

  • 12. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study.
    Hotta N, Kakuta H, Sano T, Matsumae H, Yamada H, Kitazawa S, Sakamoto N.
    Diabet Med; 1993 Mar; 10(2):134-8. PubMed ID: 8458189
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.
    Coniff RF, Shapiro JA, Seaton TB.
    Arch Intern Med; 1994 Nov 14; 154(21):2442-8. PubMed ID: 7979840
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
    Rosenstock J, Brown A, Fischer J, Jain A, Littlejohn T, Nadeau D, Sussman A, Taylor T, Krol A, Magner J.
    Diabetes Care; 1998 Dec 14; 21(12):2050-5. PubMed ID: 9839093
    [Abstract] [Full Text] [Related]

  • 15. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.
    Bayraktar M, Van Thiel DH, Adalar N.
    Diabetes Care; 1996 Mar 14; 19(3):252-4. PubMed ID: 8742572
    [Abstract] [Full Text] [Related]

  • 16. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.
    Diabetes Care; 1998 May 14; 21(5):701-5. PubMed ID: 9589227
    [Abstract] [Full Text] [Related]

  • 17. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
    Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM.
    Ann Intern Med; 1994 Dec 15; 121(12):928-35. PubMed ID: 7734015
    [Abstract] [Full Text] [Related]

  • 18. Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.
    Inoue I, Takahashi K, Noji S, Awata T, Negishi K, Katayama S.
    Diabetes Res Clin Pract; 1997 Jun 15; 36(3):143-51. PubMed ID: 9237780
    [Abstract] [Full Text] [Related]

  • 19. One-year acarbose treatment raises fasting serum acetate in diabetic patients.
    Wolever TM, Radmard R, Chiasson JL, Hunt JA, Josse RG, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH.
    Diabet Med; 1995 Feb 15; 12(2):164-72. PubMed ID: 7743764
    [Abstract] [Full Text] [Related]

  • 20. [Effect of acarbose on carbohydrate and lipid metabolism in type II diabetes with secondary failure].
    Heuer LJ, Kaufmann HH.
    Dtsch Z Verdau Stoffwechselkr; 1985 Feb 15; 45(2):52-8. PubMed ID: 3924553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.